GELFOND RICHARD L 4
4 · IMAX CORP · Filed Apr 20, 2026
Research Summary
AI-generated summary of this filing
IMAX CEO Richard Gelfond Exercises Options, Sells Shares
What Happened
Richard L. Gelfond, CEO of IMAX Corp (IMAX), exercised stock options and immediately sold the resulting shares under a 10b5-1 plan. On 2026-04-16 he converted 41,737 options into common shares at an exercise price of $31.40 (value of shares on exercise = $1,310,542) and sold those 41,737 shares in the open market at $37.05 for proceeds of $1,546,339. On 2026-04-17 he converted 34,182 options at $31.40 (value = $1,073,315) and sold those 34,182 shares at $37.06 for proceeds of $1,266,689. Total shares sold = 75,919 for total gross proceeds of approximately $2.81M.
Key Details
- Transaction dates & prices:
- 2026-04-16: Converted 41,737 options at $31.40; sold 41,737 shares at $37.05.
- 2026-04-17: Converted 34,182 options at $31.40; sold 34,182 shares at $37.06.
- Money involved: total proceeds ≈ $2,813,028; value on exercise (shares received) ≈ $2,383,857.
- Shares/holdings after these transactions (per filing): options outstanding 1,341,354; restricted share units 231,562; common shares 765,002.
- Notable footnotes: conversions were exercises of stock options pursuant to a 10b5-1 plan dated December 9, 2025. The options were originally issued in 2016 and expire June 7, 2026; vesting occurred in three 2016 installments.
- Filing timeliness: Form 4 was filed on 2026-04-20, within the required reporting period for the April 16–17 transactions.
Context
This was essentially a cashless exercise: options were converted into shares and the resulting shares were sold shortly thereafter under a pre-established 10b5-1 trading plan. Such transactions are commonly routine (e.g., to cover option exercise costs or diversify) and should not be taken alone as a signal of insider sentiment.
Insider Transaction Report
- Conversion
common shares
[F1]2026-04-16$31.40/sh+41,737$1,310,542→ 806,739 total - Sale
common shares
2026-04-16$37.05/sh−41,737$1,546,339→ 765,002 total - Conversion
common shares
[F1]2026-04-17$31.40/sh+34,182$1,073,315→ 799,184 total - Sale
common shares
2026-04-17$37.06/sh−34,182$1,266,689→ 765,002 total - Conversion
stock options (to buy)
[F2][F3][F4]2026-04-16$31.40/sh−41,737$1,310,542→ 1,375,536 totalExercise: $31.40Exp: 2026-06-07→ common shares (41,737 underlying) - Conversion
stock options (to buy)
[F2][F3][F4]2026-04-17$31.40/sh−34,182$1,073,315→ 1,341,354 totalExercise: $31.40Exp: 2026-06-07→ common shares (34,182 underlying)
- 765,002
common shares (opening balance)
Footnotes (4)
- [F1]Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated December 9, 2025.
- [F2]These options were issued in 2016 and are set to expire on June 7, 2026.
- [F3]The stock options became exercisable in three installments: 162,095 on each of June 7, 2016 and September 1, 2016 and 162,094 on December 31, 2016.
- [F4]This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,341,354, 231,562 and 765,002, respectively.